What changed in this filing

/stocks — the workspaceLOADING

Item 5. Other Information

2022-05-16 compared with 2021-11-22 · 31 added, 54 removed, 9 unchanged (90% of the section changed)

3 unchanged sentences

on its behalf by the undersigned, thereunto duly authorized.

November 22, 2021

Dennis M McGrath

and Chief Financial Officer

Financial and Accounting Officer)

of Incorporation (1)

of Amendment to Certificate of Incorporation (1)

of Amendment to Certificate of Incorporation, dated October 1, 2018 (6)

of Amendment to Certificate of Incorporation, dated June 26, 2019 (7)

of Amendment to Certificate of Incorporation, dated July 24, 2020 (10)

of Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock (8)

of Elimination - Series A Convertible Preferred Stock and Series A-1 Convertible Preferred Stock (4)

Amended and Restated Bylaws (9)

Common Stock Certificate (1)

Series W Warrant Certificate (1)

W Warrant Agreement, dated April 28, 2016, between Continental Stock Transfer & Trust Company and the Registrant (2)

Series Z Warrant Certificate (3)

and Restated Series Z Warrant Agreement, dated as of June 8, 2018, by and between PAVmed Inc.

and Continental Stock Transfer &

Trust Company, as Warrant Agent (5)

License Agreement, dated as of May 20, 2019, by and between PAVmed Inc.

and Lucid Diagnostics Inc.

Management Services Agreement, dated as of May 12, 2018, by and between PAVmed Inc.

and Lucid Diagnostics Inc.

Amendment to Management Services Agreement, dated as of March 1, 2019, by and between PAVmed Inc.

and Lucid Diagnostics Inc.

Second Amendment to Management Services Agreement, dated as of June 5, 2019, by and between PAVmed Inc.

and Lucid Diagnostics Inc.

Third Amendment to Management Services Agreement, dated as of July 20, 2020, by and between PAVmed Inc.

and Lucid Diagnostics Inc.

Fourth Amendment to Management Services Agreement, dated as of February 1, 2021, by and between PAVmed Inc.

Asset Purchase Agreement, dated as of February 25, 2022, by and among LucidDx Labs Inc., Lucid Diagnostics Inc.

and ResearchDx, Inc.

(incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K filed by Lucid on March 3, 2022).

Common Stock Purchase Agreement, dated as of March 28, 2022, by and between CF Principal Investments LLC and Lucid Diagnostics Inc.

(incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed by Lucid Diagnostics on April 1, 2022).

Registration Rights Agreement, dated as of March 28, 2022, by and between CF Principal Investments LLC and Lucid Diagnostics Inc.

(incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed by Lucid on April 1, 2022).

Management Services Agreement, dated as of February 25, 2022, by and among LucidDx Labs Inc.

and ResearchDx, Inc.

(incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed by Lucid on March 3, 2022).

Employment Agreement, dated as of February 22, 2022, by and between Lishan Aklog, M.D.

and Lucid Diagnostics Inc.

Certification

of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

Certification

of Principal Financial and Accounting Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

Certification

of Principal Executive Officer pursuant to 18 U.S.C.

(incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed by Lucid Diagnostics on January 20, 2022).

Employment Agreement, dated as of February 22, 2022, by and between Dennis McGrath and Lucid Diagnostics Inc.

(incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K filed by Lucid Diagnostics on January 20, 2022).

Employment Agreement, dated as of February 22, 2022, by and between Shaun O’Neil and PAVmed Inc.

(incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed by the Company on February 24, 2022).

Employment Agreement, dated as of February 22, 2022, by and between Shaun O’Neil and Lucid Diagnostics Inc.

(incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed by Lucid Diagnostics on March 23, 2022).

Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.†

Certification of Principal Financial and Accounting Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

Certification of Principal Executive Officer pursuant to 18 U.S.C.

Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

Certification

of Principal Financial and Accounting Officer pursuant to 18 U.S.C.

Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley

Instance Document

Taxonomy Extension Schema

Extension Calculation Linkbase

Taxonomy Extension Definition Linkbase

Taxonomy Extension Label Linkbase

Taxonomy Extension Presentation Linkbase

Certification of Principal Financial and Accounting Officer pursuant to 18 U.S.C.

Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

XBRL Instance Document

XBRL Taxonomy Extension Schema

XBRL Taxonomy Extension Calculation Linkbase

XBRL Taxonomy Extension Definition Linkbase

XBRL Taxonomy Extension Label Linkbase

XBRL Taxonomy Extension Presentation Linkbase

Page Interactive Data File (embedded within the Inline XBRL document)

by reference to the Registrant’s Registration Statement on Form S-1 - SEC File No.

by reference to the Registrant’s Current Report on Form 8-K filed May 3, 2016.

by reference to the Registrant’s Current Report on Form 8-K filed April 5, 2018.

by reference to the Registrant’s Current Report on Form 8-K/A filed April 20, 2018.

by reference to the Registrant’s Current Report on Form 8-K filed June 8, 2018.

by reference to the Registrant’s Current Report on Form 8-K filed October 2, 2018.

by reference to the Registrant’s Definitive Proxy Statement on Schedule 14A filed April 30, 2019

by reference to the Registrant’s Current Report on Form 8-K filed June 27, 2019.

by reference to the Registrant’s Current Report on Form 8-K filed January 15, 2021.

by reference to the Registrant’s Definitive Proxy Statement on Schedule 14A filed June 11, 2020

Incorporated by reference to the Lucid Diagnostics Inc.’

Registration Statement on Form S-1 - SEC File No.

Filed herewith

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q

Item 5. Other Information